Semax vs DSIP: Daytime Focus Peptide vs Bedtime Sleep Peptide, Compared

Semax is a heptapeptide: Met-Glu-His-Phe-Pro-Gly-Pro. The first four amino acids are positions 4 to 7 of adrenocorticotropic hormone (ACTH), the pituitary hormone that signals the adrenal glands to make cortisol. The last three, Pro-Gly-Pro, were added to slow its breakdown. The design keeps the part of ACTH studied for attention and learning and drops the part that raises cortisol, so Semax is described as having no corticotropic activity. It is not a steroid and not a stimulant. The full reference is what is Semax.

It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and is a registered medicine in Russia, where it has been used in neurology since the 1990s for acute ischaemic stroke and chronic cerebrovascular disease.

• BDNF and TrkB. A 2006 paper in Brain Research reported that Semax raised BDNF protein and activated its receptor, TrkB, in the rat hippocampus. BDNF is the growth factor most closely tied to synaptic plasticity, which is the basis of the "cognitive" label.
• Neurotrophins in injured tissue. A 2010 paper in Cellular and Molecular Neurobiology reported increased transcription of BDNF, NGF and their receptors in the ischaemic rat cortex.
• Serotonin and dopamine signalling. Animal work describes increased serotonergic signalling, and a mouse study reported Semax increasing amphetamine-induced dopamine release.

All of the mechanism work is in animals.

The human work is Russian clinical research, mostly in stroke and cerebrovascular patients, using the nasal medicine sold there: a 1997 study of 30 acute stroke patients against 80 matched controls, a 2005 study of 187 patients with chronic cerebrovascular disease that reported good tolerability, a 2018 trial in 110 stroke-rehabilitation patients in which plasma BDNF rose, and a 2018 single-dose functional MRI study in 14 healthy adults. There is no randomized, placebo-controlled trial in an English-language peer-reviewed journal, and no trial of Semax for focus or memory in healthy adults.

DSIP is a nonapeptide, nine amino acids long: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. In the early 1960s Marcel Monnier's group in Basel reported that blood from the brain of a sleeping rabbit could induce sleep-like EEG patterns in a second rabbit. The factor was isolated and synthesised by 1977, and a Proceedings of the National Academy of Sciences paper that year named it. The World Health Organization later gave it the nonproprietary name emideltide, which is the name the FDA uses. It is not a hormone, not related to melatonin, and not a sedative. The full reference is what is DSIP.

• Deep-sleep EEG patterns. The defining observation, repeated in rabbits, rats and cats from 1977, is more delta-wave and spindle activity, the EEG hallmarks of deep non-REM sleep. It was not universal; one 1980 rat study found no change.
• An indirect opioid route. In rats the opioid blocker naloxone stopped DSIP prolonging sleep. Cell work found DSIP does not bind opioid receptors directly but was reported to trigger release of the body's own enkephalins.
• The stress axis. A 1985 paper in Neuroendocrinology reported DSIP reduced stress-hormone release in rats, and a 2001 paper in Stress found reduced stress-induced activation in the rat hypothalamus.
• A very short life. DSIP lasts about eight minutes in human plasma before blood enzymes break it apart. Any effect is a signalling event, not a level held through the night.

Nearly fifty years on, no gene encoding DSIP and no DSIP receptor has been identified, and a 2006 review in the Journal of Neurochemistry called the sleep-factor hypothesis "extremely poorly documented and still weak."

DSIP is unusual among compounded peptides because it has small randomized, double-blind, placebo-controlled studies in people, all intravenous and all from 1981 to 1992. The first, in the Lancet in 1981, gave six chronic insomniacs an infusion or placebo and reported longer, less interrupted sleep without daytime sedation. Two independent groups did not agree: a 1987 crossover study in the International Journal of Clinical Pharmacology Research found no significant difference from placebo nights, and a 1992 study of sixteen insomniacs in Neuropsychobiology judged the effects weak. The FDA counted roughly 209 people across all of this work. There are no trials of the subcutaneous route.

Semax is the usual conversation when the complaint is daytime: difficulty concentrating, mental fatigue in the afternoon, trouble getting started on tasks, while sleep itself is reasonable. It has the longer record of human use and a clearer mechanism story. Semax benefits sets out what the research has looked at, and Selank vs Semax covers its calmer sibling.

DSIP is the usual conversation when nights are the problem: waking repeatedly, sleep that feels light, or poor sleep layered on top of a stressful stretch. The animal work on the stress axis leans toward it being most relevant when stress is driving the poor sleep; long-standing chronic insomnia is the population where the human studies split. DSIP benefits covers the research in more detail.

Brain fog after bad nights is a sleep question first. The Semax reference itself lists poor sleep as the case where DSIP or the SERENITY Blend is the conversation to have instead. Be honest on your intake about how you sleep.

They are taken at different times of day and act through different described pathways. No study has tested the pairing, so it means two unknowns at once. Whether a combination fits you is something your physician sets after reviewing your intake, and starting with one makes it easier to tell what is doing what.